Behavioral phenotyping represents a central pillar of contemporary behavioral neuroscience, offering a functional readout of neural integrity that cannot be captured solely through molecular or histological markers. In Alzheimer’s disease (AD), where cognitive decline, emotional dysregulation, and disruptions in adaptive behavior emerge long before overt neuropathology is detectable, behavioral assays provide an indispensable tool for characterizing therapeutic potential. This study underscores the critical role of behavioral testing in evaluating ten phytochemical extracts derived from Rubus fruticosus(FT,LT,FH,LH,PFH,PLH), Abutilon pannosum(A2), Abutilon grandifolium(A1), Rheum palmatum(R), and Zingiber officinale(G) in the 5xFAD transgenic mouse model, integrating in silico predictions with multidimensional behavioral outcomes.
Pharmacokinetic and target-prediction analyses suggested favorable absorption, strong blood–brain barrier permeability, and potential engagement with pathways implicated in synaptic plasticity and neuroprotection. However, behavioral assays were essential for determining whether these theoretical properties translated into meaningful functional effects. A comprehensive battery was employed to probe complementary cognitive and affective domains: Y-Maze for working memory, Novel Object Recognition for recognition memory, Radial Arm Maze for spatial learning, Open Field and Elevated Plus Maze for locomotion and anxiety-like behavior, and Forced Swimming for depressive-like responses.
Behavioral outcomes revealed extract-specific signatures that were not predictable from computational data alone. Most extracts displayed an inverse dose-dependent pattern, with lower doses producing more pronounced improvements in memory performance and emotional regulation, often surpassing the effects of the reference treatment. In contrast, other extracts followed a classical dose-response profile, enhancing cognition at higher doses and increasing exploratory behavior at lower doses.
These findings highlight the irreplaceable value of behavioral testing as a functional bridge between in silico predictions and neurobiological mechanisms. By capturing complex, systems-level outcomes, behavioral assays remain essential for identifying promising neuroactive compounds and for advancing translational research in AD.
